

**HHSC: Texas HIV
Medication Advisory
Committee
July 30, 2021**

[Texas HIV Medication Advisory Committee\(link is external\)](#) advises in the development of procedures and guidelines for the Texas HIV Medication Program, reviews program's goals and aims, evaluates ongoing efforts, and recommends short-range and long-range goals and objectives.

<ul style="list-style-type: none"> • Natalie Vanek - Committee Chair Houston, Texas Term expires 2020 • Frank Rosas - Committee Vice-Chair San Antonio, Texas Term expires 2022 • Margaret Adjei San Antonio, Texas Term expires 2022 • Ogechika Karl Alozie El Paso, Texas Term expires 2022 • Gloria Heresi Houston, Texas Term expires 2024 • Lionel Hillard Dallas, Texas Term expires 2022 	<ul style="list-style-type: none"> • Susana Lazarte Dallas, Texas Term expires 2020 • Nancy Miertschin Houston, Texas Term expires 2024 • Ray Moore Granbury, Texas Term expires 2024 • Yolanda Rodriguez-Escobar San Antonio, Texas Term expires 2024 • Demetra Tennison Austin, Texas Term expires 2024
---	--

Call to Order, Welcome and Opening Remarks – Natalie Vanek, M.D., Committee Chair.
The meeting was called to order by the Chair.

Logistical Announcement and Roll Call – Sallie Allen, Advisory Committee Coordination Office, HHSC. A quorum was established.

Consideration of January 29, 2021 and April 30, 2021, meeting minutes. The minutes were approved as written.

Department of State Health Services Updates – Imelda Garcia, MPH Associate Commissioner.

- The program was moved back under Ms. Garcia
- Pharmacy Branch reports now directly to the division
- Internal Audit Report was released, and they are working to address the 73 recommendations
- \$36 million was appropriated by the Conference Committee and additional GR was provided for the medications program

- We have to look at client growth and cost growth. Cost containment measures may have to occur.
- We are in a holding pattern on the spend down
- Changes to rider 26 expands upon insurance purchasing but this was struck by the legislature but some of the provisions in the rider will be moving forward for transparency.

Questions/Answers/Comments

Will TIAP still be offered (Insurance Assistance)? DSHS stated that the intent is to honor those already in the program, but no expansion is anticipated. If HRSA agrees then they may extend the grace period.

TB/HIV/STD Section Updates - Felipe Rocha, MSSW, Director TB/HIV/STD Section (THMP Budget report and Moving Forward Together meeting summary)

Monthly THMP Financial Report

7/29/2021

ABEST Fund	ABEST Fund Description	BY 2020	BY 2021				BY 2022
		EXPENDED	BUDGETED	OBLIGATED	EXPENDED	REMAINING	BUDGETED
001	General Revenue	\$0	\$1,500,000	\$0	\$1,500,000	\$0	\$5,693,151
8005	GR Match/MOE for HIV Care Formula Grants	\$12,839,862	\$12,037,021	\$2,254,523	\$9,632,672	\$149,825	\$14,039,065
8149	HIV Vendor Drug Rebates	\$13,586	\$5,358,830	\$24,153	\$5,274,677	\$60,000	\$15,552,875
0325	21.019.119 - Coronavirus Relief Fund	\$0	\$34,400,000	\$0	\$33,900,000	\$500,000	\$0
555	93.917.000 - HIV Care Formula Grants	\$107,314,285	\$104,246,411	\$49,035,868	\$54,590,141	\$620,402	\$68,613,305
	93.994.000 - Maternal & Child Hlth Svcs Block Grant	\$0	\$4,800,000	\$0	\$4,800,000	\$0	\$0
666	Appropriated Receipts - Misc (Rx refunds; 3rd party)	\$1,528,025	\$0	\$0	\$0	\$0	\$0
	Total All Funds	\$121,695,758	\$162,342,262	\$51,314,545	\$109,697,490	\$1,330,227	\$103,898,396

NOTES:

State Budget Year (BY) September 1-August 31 annually. Obligated funding is on a PO for the current BY.

Due to rebate shortfall, BY2021 has one-time funding from other DSHS appropriations in addition to Coronavirus Relief Funds that are not typically available within this appropriation including the \$1.5M GR fund.

Due to the infusion of CRF funds, an estimated \$30M of the \$50.4M in BY21 'obligated' HIV Care Formula Grants will roll forward from BY 2021 to BY 2022 September 1, 2021.

Total EI for FY22 is \$8,164,958 and same for FY23

EI is represented in FY22 budget as, Fund 001 for \$5,693,151 and Fund 8005 for \$2,471,807

June 30, 2021 Partnership Meeting

- 276 stakeholders registered and 198 attended the meeting
- Imelda Garcia, Associate Commissioner, of the Laboratory and Infectious Disease Services (LIDS) Division was also in attendance
 - TB/HIV/STD Section is back reporting to LIDS
- Exceptional Item (EI)
 - 36.3 million awarded from the 87th Texas Legislature
 - 16.3 million for medications
 - 20 million for restoration of Ryan White, HIV Prevention, and Public Health Follow-up Contracts
- Rider 26
 - ADAP cannot be used for health insurance expansion
 - Texas Insurance Assistance Program (TIAP) can continue and accept new clients as eligible
 - Any changes to the Texas Administrative Code (TAC) will require the community be notified 60 days in advance
- DSHS does not plan to implement a waitlist for the next biennium

June 30, 2021 Meeting Updates

- Spenddown/ Standard Deduction
 - Potential need to remove the spenddown
 - Later introduce a standard deduction once the TAC is updated
- The pharmacy warehouse is now reporting directly to the LIDS Division
- Take Charge Texas Portal
 - Rollout end of 2021
- Medication formulary changes
 - DSHS Commissioner approved the suspension of 17 medications
 - Cabenuva pilot delay
 - Daraprim back in stock
- THMP working overtime to address the backlog
- Implementation of full THMP recertification process
 - Need to stay compliant with grant expectations following relaxed COVID eligibility

Next Partnership Meeting

- Batch 3 FAQs have been posted
 - 43 more questions were received from stakeholders during the meeting
 - Additional FAQs were added, creating two additional batches (batches 5 & 6)
- Moving Forward Together Draft Plan
 - Posted 7/21/2021
 - Comment/feedback period closes 9/1/2021
- Next meeting will be in the fall
 - DSHS proposing Wednesday September 29, 2021
- Next meeting will be shorter
 - 12:00 -2:30 pm
- Format
 - Updates (requested by stake holders)
 - Q & A instead of Discussion

Questions/Answers/Comments

Does this consider cost and client growth? DSHS stated that this has sufficient funding for 2022. Opportunities for supplement funding will be available as well.

This is a good budget report compared to those in the past.

We are operating under a “Just in time model” and as such we do not keep stockpiles of inventory on the shelf.

The CDC numbers for HIV in Harris County are down and is this the experience across the state? DSHS stated that the Texas numbers are different. 2020 was strange because of COVID.

THMP Update - Rules change, Projections and demographic information, Long-lasting injection medication update. Rachel Sanor, THMP Manager

**Texas HIV State Pharmacy Assistance Program
and Texas HIV Medication Program
Title 25, Chapter 98,
Subchapters A and C, Division 1**

- Rules change includes the following:
 - Includes the Texas Insurance Assistance Program (TIAP).
 - Merges State Pharmacy Assistance Program (SPAP) and Texas HIV Medication Rules into one set of rules.
 - Removes a specific FPL from the rules, this will be determined at the department level instead.
 - Removes spend down and replaces it with a standard deduction.
 - Updates language to reflect current structure of program.
- The informal comment period was extended from July 7th to July 16, 2021.
- A second, formal comment period will be when they are posted on the Texas Register for 30 days.

ADAP Utilization

Month	Total Client Served	Total Prescriptions Filled
September 2020	8,001	10,143
October 2020	7,744	9,808
November 2020	9,659	12,378
December 2020	12,546	16,983
January 2021	10,350	13,156
February 2021	8,768	11,029
March 2021	10,821	14,429
April-2021	10,773	14,003
May 2021	10,166	13,078


7/30/2021

Data From Texas HIV Medication Interface, July 15, 2021.

5

THMP Medications Ordered for Q2 2021

Medications Ordered N=35,208




Texas HIV Medication Program Fact Sheet


April 1, 2021- June 30, 2021

Total Clients = 18,608



Reported Ethni..



Reported Race



Reported Gen..



Projected ADAP Data


Clients by Fiscal Year

2019	2020	2021	2022	2023
18,122	20,895	21,096	21,608	22,364

Measure Names


Prescriptions
Total Cost

Total Cost and Prescriptions




Data From Texas HIV Medication Interface, July 11, 2021. Projections from Rudd and Wisdom, July 13, 2021. Graph created by Matthew Estes, Epidemiologist II, Program Informatics & Evaluation; TB/HIV/STD Section

SPAP Projections



/2021

Data From Texas HIV Medication Interface, July 11, 2021. Projections from Rudd and Wisdom July 13, 2021. Graph created by Matthew Estes, Epidemiologist II, Program Informatics & Evaluation; TB/HIV/STD Section



Questions/Answers/Comments

Every year except 2020 the cost tracked along with prescriptions. In 2020 the cost was up but the prescriptions were down. DSHS stated that the COVID response skewed the data.

Backlog of ADAP applications. DSHS stated that there is a back log in the program and the self-attestations are still processing. The back log should be taken care of.

People do not know their medications are being with-held until they get to the pharmacy. DSHS stated this is a concern and they are working on the issue. Self-attestations are being certified by staff and there is a need for additional staff. The COVID extension ends at the end of next month.

Procedure for Election of New Officers – Sallie Allen, Advisory Committee Coordination Office, HHSC. The HHSC committee standard procedures were reviewed for the election of officers next meeting.

Sub-Committee Reports (Formulary Sub-committee – Natalie Vanek, M.D; Governance/Data – Nancy Miertschin; Eligibility – Frank Rosas). *There appeared to be a lack of preparation for these presentations.*

Formulary: The presentation was muffled and could not be understood. They talked about a pilot project and left it on the table. They discussed medication suspension for the ten medications suspended. They discussed a provision of three-month supply to prepare people for the transition. They were still waiting for the program funding information and as such suspended the 90 program.

Governance/Data: There have been three meetings. On May 28th they developed a statement and streamlining the certification form online, and that is ready to go. There was discussion about budget issues and preparing for new members. They received numerous updates. The pharmacy warehouse budget was discussed. Different items that were updated today at the meeting were requested. There was a desire for more transparency on how medications are added and also eliminated.

Eligibility: The July meeting was cancelled. The previous issues are available through the official documents for this meeting (*which were not provided to the public*)

Public Comment No public comment was offered.

Action items and agenda topics for next scheduled meeting November 5, 2021

- Organization Chart
- Election of officers
- Evaluation of the spend down requirement
- Re-evaluation of the 90-day supply for medication that has been suspended
- Next meeting is in November.

Adjourn There being no further business, the meeting was adjourned.

This summary contains supplemental information from third-party sources where that information provides clarity to the issues being discussed. Not every comment or statement from the speakers in these summaries is an exact transcription. For the purpose of brevity, their statements are often paraphrased. These documents should not be viewed as a word-for-word account of every meeting or hearing, but a summary. Every effort has been made to ensure the accuracy of these summaries. The information contained in this publication is the property of Texas Insight and is considered confidential and may contain proprietary information. It is meant solely for the intended recipient. Access to this published information by anyone else is unauthorized unless Texas Insight grants permission. If you are not the intended recipient, any disclosure, copying, distribution or any action taken or omitted in reliance on this is prohibited. The views expressed in this publication are, unless otherwise stated, those of the author and not those of Texas Insight or its management.
